ABT-510

ABT-510

ABT-510 is a molecular therapeutic drug used to treat cancer. According to the "Journal of Clinical Oncology", ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue in phase 2 clinical development for treatment of advanced malignancies." [Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3080] [ [http://www.jamesline.com/cancertypes/glossary/index.cfm?action=Display&ID=367468&Letter=A NCI: ABT-510 ] ]

ABT-510 is a new Abbott compound showing promise as an angiogenesis inhibitor or anti-angiogenic agent, meaning it works by stopping the growth of new blood vessels. [ [http://www.jamesline.com/cancertypes/glossary/index.cfm?action=Display&ID=367468&Letter=A NCI: ABT-510 ] ] This Thrombospondin 1 mimetic works through CD36 and has been shown to block angiogenesis in vitro and in vivo and to slow tumor growth in mice.

ABT-510 was shown to be effective in both xenograft models [Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL. (2007) Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67(4):1716-24] and in a study of companion dogs with spontaneous tumors. Not only were objective responses observed after 60 days, but a decrease in levels of circulating endothelial cells was also found [Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C. (2006) Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12(24):7444-55] .

In human studies, ABT-510 was found to be safe and have efficacy in phase I trials in combination regimens [Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA. (2006) A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17(8):1320-7] [Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA. (2006) Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 42(4):467-72] , and as a single agent, where its use was associated with a decrease in bFGF levels and stable disease in six patients for at least six months [Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. (2005) Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23(22):5188-97] .

The combination of bevacizumab and ABT-510 has been shown (in a phase I study) to be effective in promoting stable disease in 44% of patients with advanced solid tumors [Uronis HE, Bendell J, Blobe G, Morse M, Geier D, Nixon A, Howard L, Evans D, Li H, Hurwitz H. (2007) A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors. ASCO Proceedings Abstract 3541] .

Unfortunately, the recent phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in early termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment [Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. (2007) A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 30(3):303-9] .

References


Wikimedia Foundation. 2010.

Игры ⚽ Нужна курсовая?

Look at other dictionaries:

  • ABT-510 — A substance being studied in the treatment of cancer. It is a type of angiogenesis inhibitor …   English dictionary of cancer terms

  • 510 — Portal Geschichte | Portal Biografien | Aktuelle Ereignisse | Jahreskalender ◄ | 5. Jahrhundert | 6. Jahrhundert | 7. Jahrhundert | ► ◄ | 480er | 490er | 500er | 510er | 520er | 530er | 540er | ► ◄◄ | ◄ | 506 | 507 | 508 | …   Deutsch Wikipedia

  • Aemilianus, S. (6) — 6S. Aemilianus, Abb. (10. März). Der hl. Aemilian war in Irland geboren und hatte in seiner Jugend unter der Leitung des hl. Furseus die Anfangsgründe des christlichen Wandels erlernt. Als er später den großen Ruf von der Heiligkeit seines… …   Vollständiges Heiligen-Lexikon

  • Schwere Panzer-Abteilung — Les schwere Panzerabteilungen, ou bataillons de chars lourds, sont créés pour les premiers en mai 1942. Ils doivent accueillir les nouveaux chars Panzerkampfwagen VI Tiger, et plus tard, le Tigre II. Ces chars lourds sont censés surclasser tous… …   Wikipédia en Français

  • Thrombospondin — Thrombospondins (TSP) are secreted proteins with antiangiogenic abilities. TypesThe thrombospondins (TSP) are a family of multifunctional proteins. The family consists of thrombospondins 1 5 and can be divided into 2 subgroups: A, which contains… …   Wikipedia

  • Trombospondina — Dominio trombospondina tipo 1 Identificadores Símbolo TSP 1 Pfam PF00090 InterPro …   Wikipedia Español

  • Schwere Panzer Abteilung 502 — Période 25 mai 1942 – 9 mai 1945 Pays …   Wikipédia en Français

  • List of oncology-related terms — This is a list of terms related to oncology. The original source for this list was the U.S. National Cancer Institute s public domain Dictionary of Cancer Terms . NOTOC 1 * 10 propargyl 10 deazaaminopterin * 12 O tetradecanoylphorbol 13 acetate * …   Wikipedia

  • DTM-Saison 2011 — Die DTM Saison 2011 war die 25. Saison der DTM und die zwölfte seit Neugründung der Serie im Jahr 2000. Die Saison startete am 1. Mai und endete am 23. Oktober auf dem Hockenheimring. Inhaltsverzeichnis 1 Änderungen 2011 1.1 Reifen 2 Teams und… …   Deutsch Wikipedia

  • Teufel — (s. ⇨ Teixel). 1. A mol muess ma m Teuffel uff de Wedel treta. – Birlinger, 1036. 2. All, wat de Düwel nich lesen kann (will), dat sleit he vörbi (oder: sleit he äwer). – Frommann, II, 389, 123; Eichwald, 346; Goldschmidt, 57; Kern, 1430. 3. Als… …   Deutsches Sprichwörter-Lexikon

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”